ArticleEJHaem2026
A Real-World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tafasitamab, a CD19-targeting immunotherapy, is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplant. This real-world study describes patient characteristics, treatment patterns, and outcomes associated with tafasitamab for R/R DLBCL across US practice settings. Methods: A retrospective physician-abstracted chart review was conducted among US adults initiating tafasitamab (with/without lenalidomide) for R/R DLBCL as part of routine clinical care. Data were summarized using descriptive statistics. Cox proportional hazards-based analyses were performed to determine baseline characteristics associated with real-world progression-free survival and overall survival. Results: Twenty-three physicians (83% community physicians) provided data on 181 patients (64% White; median follow-up since initiation, 14.7 months) meeting eligibility criteria. Most patients (72%) received tafasitamab as second-line (2L) therapy. Real-world overall response rate (95% CI) to tafasitamab was 73.5% (67.0-79.9). Median (95% CI) real-world progression-free survival and overall survival from tafasitamab initiation were 11.3 (9.8-13.6) and 24.8 (17.8-NE) months, respectively. In multivariable Cox proportional hazards-based analyses, tafasitamab use in third-line to fifth-line (3L-5L) (vs. 2L), bulky disease (vs. non-bulky), Ann Arbor Stage III-IV (vs. stage I-II), and increasing Charlson Comorbidity Index scores were determined as factors associated with increased progression risk. In addition, increasing age, tafasitamab in 3L-5L (vs. 2L), bulky disease (vs. non-bulky), and Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 (vs. < 2) were associated with higher mortality risk. Conclusion: This analysis of a diverse US population who received tafasitamab for R/R DLBCL predominantly in community practice settings supports the clinical benefit of tafasitamab. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.